진행성 대장암에 대한 Leucovorin, 5-Fluorouracil 및 Cisplatin(LV-FP) 복합화학요법의 치료효과
Leucovorin, 5-Fluorouracil and Cisplatin(LV-FP) Chemotherapy for Advanced Colorectal Cancer
소속 상세정보
유영진
임영혁/강윤구/김봉석/김형건/손태용/이상구/천은미/김유철
KMID : 0360319950270010044
Abstract
The biochemical modulation of 5-fluorouracil(5-FU) by leucovorin has been demonstrated to enhance the activity of 5-FU in patients with advanced colorectal cancer and the synergism between 5-FU and cisplatin is well known in advanced
gastrointestinal
tract cancers. We conducted a phase Ⅱtrial to evaluated the effect of a combination of leucovorin, 5-FU, and cisplatin(LV FP)in patients with advanced colorectal cancer. LV-FP regimen consisted of leucovorin 20mg/m*/day Ⅳ in day 1~5, 5-FU
1.000mg/m*/day continuous Ⅳ. Infusion in day 1~5, and cisplatin 20mg/m*/dayⅣin day 1~5. The regimen was repeated every 3 weeks. Among 46 patients with histologically confirmed advanced colorectal adenocarcinoma, 31 patients had measurable
lesion(s)
with median age of 55 years(22~ 70 years). 27 patients had previous history of chemotherapy and 19 were previously untreated.
There was no complete response. 11 patients responded partially to the regimen to make the response rate 35%(11/31). The median time to progression was 16 weeks(2~44 weeks), and the median survival time was 42 weeks(1+~80 weeks). There was no
difference
I response rates between the previously treated and the previously untreated. Hematologic toxicities were mild and non-hematologic toxicities were also tolerable. There was no treatment-related mortality.
These results indicate that the LV-FP regimen is safe and effective in advanced colorectal adenocarcinoma.
키워드
원문 및 링크아웃 정보
등재저널 정보